GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Status and phase: Unknown; Phase 4

Conditions: Essential Hypertension

Treatments: Drug: Candesartan

Study type: Interventional

Funder types: Other

Identifiers

NCT01629225

ThirdMMU

Details and patient eligibility

About

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

Full description

All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.

Enrollment: 500 estimated patients

Sex: All

Ages: 30 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• men and women with mild to moderate essential hypertension in southwestern Han Chinese

Exclusion criteria

• subjects unwilling to participate or subjects did not have all measurement required,
• subjects who were on medications, which affect blood pressure or
• whose DNA failed to amplify and 8 with errors in Mendelian segregation

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Single Blind

---

500 participants in 1 patient group

candesartan

No Intervention group

Description:

All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.

Treatment:

Drug: Candesartan